QuidelOrtho Reports Third Quarter 2026 Financial Results

What happened

QuidelOrtho reported third-quarter 2026 revenue of $619 million, down 12% year over year. Labs revenue fell 6%, mainly because of lower China sales following changes to diagnostic-test pricing, while Labs revenue outside China grew 3%. Immunohematology revenue was flat overall and grew 2% outside China.

Confirmed

Global impact / market context

The results show that weaker sales in China and other excluded business areas outweighed growth in Labs and Immunohematology elsewhere. If that pattern persists, total revenue could remain under pressure even as some operations expand; the announced savings program may help offset costs, but its delivery is not established here.

Analyst inference

The company says its new cost transformation and restructuring program is expected to produce more than $80 million in annual savings in 2027, and that it narrowed its full-year 2026 guidance ranges. These are management expectations, not reported savings or finalized results.

Confirmed

What to watch

1. Check later reports for whether revenue outside China continues growing and whether China pricing changes keep weighing on Labs sales, since these trends affect overall revenue. Analyst inference
2. Look for details on the cost transformation and restructuring program, including implementation costs and progress toward the expected annual savings of more than $80 million in 2027. Proposed
3. Review the full-year 2026 guidance ranges and subsequent results to see how the narrowed outlook compares with actual revenue and operating performance. Analyst inference

Evidence

• Original source link unavailable